B. Murrell

Antigen affinity and site of immunization dictate B cell recall responses

This study shows that antigen affinity and immunization site influence B cell recall responses, with low affinity boosts leading to higher SHM but fewer memory B cells in secondary GCs.

Neutralisation sensitivity of the SARS-CoV-2 BA.2.87.1 variant

This study characterizes the neutralization sensitivity of the SARS-CoV-2 BA.2.87.1 variant and shows it is less resistant to antibodies than other variants, with a booster increasing neutralizing titers.

Full-spike deep mutational scanning helps predict the evolutionary success of SARS-CoV-2 clades

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

Sensitivity of BA.2.86 to prevailing neutralising antibody responses

This study assesses BA.2.86's sensitivity to neutralising antibodies using monoclonal antibodies and serum samples from Stockholm.

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies

The paper evaluates neutralisation resistance of Omicron sublineages BA.2.75.2, BA.4.6, and BA.2.10.4, finding BA.2.75.2 shows extensive escape from neutralising antibodies.

Evasion of neutralizing antibodies by Omicron sublineage BA.2.75

This study evaluates the neutralization sensitivity of the SARS-CoV-2 BA.2.75 sublineage to monoclonal antibodies and sera from individuals infected with earlier variants.

Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function

The paper identifies 13 rare mutations in the Omicron S-gene that cluster in functionally important regions and likely impact Spike function, suggesting cooperative interactions that mitigate fitness costs.

Structural basis of Omicron neutralization by affinity-matured public antibodies

The paper identifies affinity-matured antibodies that neutralize SARS-CoV-2 Omicron with high potency and resolves their structure to explain cross-neutralization.

Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)

This study assesses neutralizing antibody responses against the SARS-CoV-2 Omicron variant, showing reduced potency compared to the pandemic founder but with some cross-neutralizing capacity in vaccinated individuals.

Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies

This study identifies potent cross-neutralizing SARS-CoV-2 nanobodies from an alpaca immune repertoire using phage display and epitope mapping.

Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost

A single dose of a VOC-derived RBD protein boost enhances potent neutralizing antibodies against both Wu-Hu-1 and the VOC in previously vaccinated rhesus macaques.

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo

A bispecific nanobody neutralizes SARS-CoV-2 and its variant B.1.351 by inducing spike trimer-dimers that prevent ACE2 binding.

Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2

Single-cell sequencing and screening identify expanded plasma cell clones in COVID-19 patients producing SARS-CoV-2-specific neutralizing antibodies.

Sublingual allergen immunotherapy with recombinant dog allergens prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses

This study shows that sublingual immunotherapy with recombinant dog allergens reduces airway hyperresponsiveness and type 2 inflammation in a mouse model of dog allergy.

SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses

This study shows that SARS-CoV-2 spike protein subunit vaccines induce strong neutralizing antibodies in mice and macaques, with high titers after a single dose or dose-sparing regimen.

Discriminative Bayesian Serology: Counting Without Cutoffs

The paper develops a Bayesian method to estimate seroprevalence without cutoffs, accounting for uncertainty in serological assay data and infection status.

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

This study isolates and characterizes synthetic nanobodies that neutralize SARS-CoV-2, identifying Sb23 with high affinity and neutralization activity.

Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells

This study shows that engineered HIV bnAb-expressing B cells can be expanded in vivo after vaccination, leading to durable bnAb memory and long-lived plasma cells.

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.

Reprogramming the antigen specificity of B cells using genome-editing technologies

This study reprograms B cells to express HIV-specific BCRs by editing immunoglobulin genes with CRISPR-Cas9, enabling improved anti-HIV neutralizing activity.

Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance

This study shows that slow delivery immunization in rhesus macaques increases HIV-neutralizing antibody titers and germinal center responses by modulating immunodominance.